Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020;25(6):507-513.
doi: 10.5863/1551-6776-25.6.507.

Late Acetaminophen Therapy for Patent Ductus Arteriosus in the Preterm Neonate

Late Acetaminophen Therapy for Patent Ductus Arteriosus in the Preterm Neonate

Ronnelle King et al. J Pediatr Pharmacol Ther. 2020.

Abstract

Objective: In preterm infants, the standard pharmacologic treatment for a hemodynamically significant patent ductus arteriosus (hsPDA) is either ibuprofen or indomethacin. However, these medications may be less effective after 2 weeks of age. We investigated the use of acetaminophen in hsPDA closure beyond 2 weeks of age.

Methods: An observational study of 11 infants, <30 weeks' gestation at birth and postnatal age > 2 weeks, who received acetaminophen treatment for their hsPDA. Echocardiograms (ECHOs), B-type natriuretic peptide (BNP) levels, and the fraction of inspired oxygen (FiO2) were obtained before and after treatment to analyze ductal characteristics. Renal and liver functions were monitored pretreatment and posttreatment to look for potential medication side effects.

Results: Of the 10 infants with ECHO data for before and after acetaminophen treatments, 4/10 (40%) had a decrease in PDA size, with no infants having complete closure immediately posttreatment. Eight of 11 (73%) infants had a decreased FiO2 requirement after treatment. Of the 5 infants with pretreatment and posttreatment BNP data, 2/5 (40%) infants had a decrease in BNP level. One infant received an additional course of acetaminophen. Four infants underwent a surgical ligation. Two infants died. No medication side effects occurred with regard to hepatic and renal function.

Conclusion: Acetaminophen is a safe and effective pharmacologic treatment to reduce the significance of the hsPDA in some infants beyond 2 weeks of age, as shown by ECHO and BNP data.

Keywords: acetaminophen; hemodynamically significant PDA; neonate; patent ductus arteriosus.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors declare no conflicts or financial interest in any product of service mentioned in the manuscript. BNP laboratory cartridges were provided by Quidel, Inc. Ronnelle King and Kate Tauber had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Figures

Figure 1.
Figure 1.
Population flow diagram.
Figure 2.
Figure 2.
B-type natriuretic peptide (BNP) levels before and after acetaminophen treatment.
Figure 3.
Figure 3.
Fraction of inspired oxygen (FiO2) requirement before and after acetaminophen treatment.

References

    1. Puddy VF, Amirmansour C, Williams AF, Singer DR. Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci (Lond) 2002;103(1):75–77. - PubMed
    1. Hsu JH, Yang SN, Chen HL et al. B-type natriuretic peptide predicts responses to indomethacin in premature neonates with patent ductus arteriosus. J Pediatr. 2010;157(1):79–84. - PubMed
    1. Noori S, McCoy M, Friedlich P et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics. 2009;123(1):e138–e144. - PubMed
    1. Jain A, Shah PS. Diagnosis, evaluation, and management of patent ductus arteriosus in preterm neonates. JAMA Pediatr. 2015;169(9):863–872. - PubMed
    1. Bixler GM, Powers GC, Clark RH et al. Changes in the diagnosis and management of patent ductus arteriosus from 2006 to 2015 in United States neonatal intensive care units. J Pediatr. 2017;189:105–112. - PubMed

LinkOut - more resources